Could a vaccine made from your own cancer cells beat melanoma?
NCT ID NCT01753089
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 45 times
Summary
This early-stage trial tested a new vaccine called WDVAX in 23 people with advanced melanoma. The vaccine is made from each patient's own killed tumor cells, combined with immune-boosting proteins, and formed into a small tablet. The goal was to see if it's safe and possible to create, and whether it can train the immune system to fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WDVAX (a scaffold containing killed melanoma tumor cells plus immune-boosting proteins GM-CSF and CpG)
What this could lead to
If it works, this could lead to a personalized vaccine that trains the immune system to attack melanoma, potentially offering a new treatment option.
What could go wrong
This is a very early Phase I trial with only 23 people, focused on safety and feasibility. The vaccine may not trigger a strong enough immune response or shrink tumors, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.